Antibody treatment for ‘bubble boy’ disease
In a clinical trial, participants were given an antibody to CD117, a cell surface marker, in an effort to wipe out their defective blood stem cells without high-risk chemotherapy or radiation.
Progress toward precision health
A perspective piece from Stanford scientists provides an overview of the value of precision health, its progress, challenges and how it can improve health at the individual and population level.
Magazine explores new frontiers
The winter issue of Stanford Medicine magazine highlights science that pushes boundaries to save lives and considers ethical questions that are a fundamental part of research.
How our brains prepare for action
Mentally running through a routine improves performance, but how that works isn’t clear. Now, a new tool — brain-machine interface — suggests the answer lies in how our brains prepare for action.
Ioannidis on antidepressant efficacy
In a highly comprehensive meta-analysis of more than 500 clinical trials, researchers from around the world have drawn conclusions about the efficacy of 21 different antidepressants.
Neuroscience awards named for Barres
The five-year awards from the Chan Zuckerberg Initiative will help fuel research into the biology of neurodegenerative diseases. The awards honor a Stanford neuroscientist who died in December.
Iron triggers lung transplant infection
Iron enables a common mold to take root in lung transplant recipients, according to Stanford researchers who led a study that offers a new perspective for understanding and treating these pulmonary infections.
Schneider on disease and data sculptures
Many infectious diseases, including malaria, are marked by cyclical ups and downs. David Schneider takes a creative approach to making sense of those ups and downs.
Drug Discovery Conference set for April 23-24
The two-day conference at Stanford will bring together experts from academia, industry and government to discuss drug policy, research and business opportunities.
Gerald Reaven, who coined ‘Syndrome X,’ dies
Gerald Reaven’s decades of research at Stanford helped show that insulin resistance could lead to Type 2 diabetes and multiple other diseases.